Biosimilars are at the forefront of the intellectual property and regulatory law debate in many jurisdictions worldwide. While the US and Europe are the focus of most debates, the effective regulatory and legal framework which support the emerging biosimilar market in Canada should not be overlooked. This article will provide an overview of Canada’s approach to market authorization of biosimilars and highlight why the regulatory and legal framework in Canada, which has traditionally been attractive to generic pharmaceuticals, is also attractive to biosimilars. The market demand for biosimilars is growing given the economic value of such medications and the ‘timeline’ of the relevant technology. The recombinant technology responsible for the production of biologics arose in the early 1970s. As a result, patents are now expiring and cheaper technology is becoming available. The therapeutic value of biologics is better understood and biologics such as Humulin (insulin glargine; Eli Lilly and Co., IN, USA), Neupogen (filgrastim; Amgen, Inc., CA, USA), Humira (adalimumab; AbbVie Inc, IL, USA) and Remicade (infliximab; Janssen Pharmaceutica, Beerse, Belgium) have become standard care treatments. Governments and the public are looking for lower cost alternatives to these safe and effective medications. Presently, four biosimilars have been approved in Canada: Inflectra (infliximab; Hospira, IL, USA), Remsima (infliximab; Celltrion Healthcare, Incheon, South Korea), Omnitrope (somatropin; Sandoz Inc., Holzkirchen, Germany) and Grastofil (filgrastim; Apotex Inc., Toronoto, Canada). Although the Canadian market is still young, the legal framework for approval of these products is solidly in place. From a regulatory perspective, clear guidance has been provided by Health Canada on the necessary requirements for market approval [1]. From a patent perspective, the traditional ‘patent-linkage’ system applicable to generic pharmaceuticals is also utilized for biosimilars [2].